Kornimate/medical-research-clean huggingface dataset:
precision of the magnetocardiographer for data aquision and analysis.

Conditions: Myocardial Ischemia

Summary: magnetocardiography has been extensively studied focusing on the possible clinical applications of the device. evaluating the precision of a device is a prerequisite condition to know what are significant changes and how can these be trusted. a respectable reproducibility study for the mcg measurements is crucial for this new device to be used for clinical applications. in this study, we will focus on a critical portion of the heart cycle assessing for changes in time of the computerized analysis of this phase and comparing the analysis done by two examiners.

the studies involving magnetocardiography have almost exclusively focused on evaluating possible clinical applications of the device. leder et al saw the need for investigating the reproducibility of high temperature superconducting (hts-)mcg measurements. they tested 18 healthy volunteers, stating that assessment of the reproducibility of hts-mcgs in the normal heart is a prerequisite condition for the definition of significant levels of changes which, for instance, may be observed in serial measurements of patients suffering from acute coronary syndromes. they also pointed out the potentially strong electromagnetic interference inside a hospital, likely to be very different from the noise found in engineering laboratories where the mcgs are originally calibrated and tested. a respectable reproducibility for the mcg measurements is crucial for clinical applications. leder et al studied the reproducibility of qrs complexes, st segments, and t waves. they found that the reproducibility of the measurements in the depolarization phase was high, whereas the reproducibility of their repolarization readings was considerably lower. the results led leder et al to conclude that further technical development was needed to improve signal-to-noise ratio allowing for clinical application of repolarization abnormalities for recognizing acute coronary syndromes. in this study, we will focus on the repolarization phase by assessing the reproducibility of the t wave only. comparison of scores and results based on computer analyses will provide the basis for our evaluation. visual interpretations by the two examiners will also be compared.

Eligibility criteria:
age less than or equal to 45 years
effect of citrate on the coagulation system in patients receiving crrt

Conditions: Acute Kidney Failure

Summary: the aim of this study is to evaluate the effect of regional citrate anti-coagulation on different pathways of the coagulation system in critically ill patients with acute kidney injury. this will form the basis for future studies where the investigators plan to focus on patients with premature circuit clotting despite optimal post-filtrate ionised calcium parameters.

purpose of clinical trial: to evaluate the effect of regional citrate anti-coagulation on different pathways of the coagulation system in critically ill patients with acute kidney injury. patient population: critically ill patients with acute kidney injury requiring citrate-based continuous renal replacement therapy (crrt) primary objective: changes from baseline in a number of measures of coagulability (platelet count; prothrombin time; activated partial thromboplastin time ratio; fibrinogen; d-dimers; thrombin generation assay; clot lysis; platelet function analysis 100) in both the blood within the patient's systemic circulation and the crrt circuit over the course of 72 hours of regional anticoagulation with citrate. number of subjects/patients: 12 patients with complete data. trial design: prospective non-interventional study. endpoints: change from baseline in a number of measures of coagulability. main inclusion criteria: adult intensive care patients undergoing crrt with citrate regional anti-coagulation for aki.

Eligibility criteria:
inclusion criteria: * acute kidney injury treated with citrate based continuous renal replacement therapy (crrt) * age \>18 years. * expected to require \>72 hours of crrt. exclusion criteria: * known preexisting clotting tendency * known preexisting bleeding tendency * disseminated intravascular coagulation (dic) * prior transfusion of any blood product in the 24 hours before enrolment * active bleeding (ie. needing blood transfusion) at time of enrolment * haemoglobin at time of enrolment \<75g/l * haematocrit at time of enrolment \>0.55 * patient would refuse red blood cell transfusion (for example jehova's witness). * platelet count at time of enrolment \<100x103/µl * treatment with any anticoagulant or antiplatelet agent at time of enrolment or within 7 days of enrolment with the exception of heparin or low molecular weight heparin for dvt prophylaxis. * intravenous heparin exposure within 4 hours of commencing citrate anticoagulation. * malnourished: bmi \ 10% actual body weight (abw) in preceding 6 months or bmi \ 5% abw in preceding 6 months. * crrt prescribed for an indication other than aki (for example poisoning).
using smart experimental design to personalize treatment for child depression

Conditions: Depression

Summary: the purpose of the study is: 1. to conduct a pilot smart (sequential, multiple assignment, randomized) study with the long-term goal of developing a personalized treatment for child depression. 2. to collect pilot data on ways to personalize treatment for child depression using cognitive behavioral therapy (cbt), caregiver-child treatment, or both.

child depression is among the most prevalent and impairing pediatric conditions and constitutes a major public health concern. unfortunately, treatment benefits are relatively modest and short-lived with sizeable percentages of children who maintain depressive symptoms following treatment. this problem may be addressed in part by personalizing treatment, including determining which children will benefit from cbt, which children will benefit from caregiver-child treatment, and which children will benefit from both. the goal of the current study is to pilot test an innovative experimental design called sequential, multiple assignment, randomized trial (smart), which is used for development of personalized treatments, collect pilot data, and assess the acceptability and feasibility of using this design, in preparation for a full-scale smart in a larger clinical trial and for the development of personalized treatment.

Eligibility criteria:
inclusion criteria: 1. current diagnosis of major depressive disorder (mdd), dysthymic disorder (dd), or depressive disorder not otherwise specified (nos). 2. if receiving psychiatric medication, dose should be stable for at least three months at enrollment. exclusion criteria: 1. a disorder other than depression as primary diagnosis. 2. autism spectrum disorders and pervasive developmental delay or disorder. 3. mental retardation. 4. psychotic disorders and schizophrenia. 5. mania or hypomania disorders. 6. acute suicidal behavior and/or acute plan that require higher level of care, and being hospitalized over the past year for a suicide attempt or for threatening to commit suicide. 7. participation in additional psychotherapy. 8. caregiver and/or children do not speak english.

Keywords: depression, child, cbt, parent training, personalized treatment
a study to evaluate the clinical outcomes of efgartigimod ph20 sc in adults with new-onset generalized myasthenia gravis (gmg)

Conditions: New Onset Generalized Myasthenia Gravis (gMG)

Summary: the main purpose of this study is to measure how well adults with new-onset gmg (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod ph20 sc. the study consists of a treatment period of 51 weeks. the study duration for each participant will be approximately 58 weeks.


Eligibility criteria:
inclusion criteria: * is at least 18 years when signing the icf * has been diagnosed with gmg of mgfa class ii, iii, or iv * is seropositive for achr-ab * is treatment-naive for gmg or has been administered achei for the treatment of gmg * had onset of generalized mg signs and/or symptoms within 12 months before screening; candidates who also had onset of ocular mg signs and/or symptoms within 24 months before screening may be enrolled in the study * has an mg-adl score ≥5 exclusion criteria: * gmg diagnosis of mgfa class i or v * underwent a thymectomy prior to screening, except thymectomy for treatment of nonmalignant thymoma prior to the gmg diagnosis * prior or current use of any of any systemic corticosteroid therapy or nonsteroidal immunosuppressive therapy for the treatment of gmg
cardiac management of patients with thalassemia minor and breast cancer

Conditions: Breast Cancer; Thalassemia Minor; Heart Diseases

Summary: this retrospective study aimed to evaluate the demographic characteristics, clinical conditions in term of physical examination findings), functional status, and laboratory results of patients with thalassemia minor (tm) and breast cancer (bc) in order to identify any differences between the group with bc only. available data as anticancer treatment, comorbidities, weight and height will be combined to report body mass index (bmi) in kg/m2, systolic and diastolic blood pressure, heart rate, ecg, transthoracic echocardiography, blood count, lipid panels, glucose, kidney function tests, (n terminal) nt-probnp, troponins, handgrip assessments, functional status were extracted from patients files and hospital electronic archives.

following data was extracted from files and hospital electronic records, and will be evaluated (at baseline, 3, 6, 9 and 12 months): 1. physical examination findings (as pretibial edema, jugular venous distension, lung rales), 2. clinically significant changes in cardiac function as determined by left ventricular ejection fraction (lvef) measurements using transthoracic echocardiography, 3. any changes in (n terminal) nt-probnp and troponin, 4. any changes in manual handgrip measurements for both hands using hydraulic hand dynamometer, 5. applied medications, were extracted and will be evaluated.

Eligibility criteria:
inclusion criteria: 1. patients with diagnosis of breast cancer, and thalassemia minor, 2. \>18 years old, 3. referred by oncologist for cardiac evaluation. 4. patients with available cardiac evaluations data at baseline and during breast cancer treatment exclusion criteria: 1. patients without diagnosis of breast cancer, and thalassemia minor, 2. \<18 years old, 3. patients without any cardiac evaluations at baseline, and during cancer treatment. 4. patients with history of any cardiotoxic treatment prior to enrolment.

Keywords: cardiotoxicity cancer treatment related cardiac dysfunctions
prevalence and factors of sarcopenia and in patients with primary sjogren's syndrome

Conditions: Sarcopenia; Sjogren's Syndrome; Rheumatologic Disease

Summary: sarcopenia is a progressive condition characterized by decline in muscle strength and muscle mass. although the mechanism of sarcopenia has not been fully elucidated, it may be caused by protein-poor diet, vitamin d deficiency, hormonal changes, increase in inflammatory cytokine level and oxidative stress. for this reason, it is thought that determining the prevalence of sarcopenia in rheumatological diseases with chronic inflammation and protecting patients from possible comorbidities with appropriate interventions may be an important factor in maintaining and improving the functional levels and quality of life of patients. the aim of our study was to investigate the prevalence and its associated factors of sarcopenia in individuals with primary sjögren's syndrome.


Eligibility criteria:
inclusion criteria: * diagnosed with primary sjogren's syndrome by an experienced rheumatologist according to european league against rheumatism (eular) ve american college of rheumatology (acr) criteria * being 40 years or older. exclusion criteria: * pregnancy, * malignancy, * presence of other rheumatological diseases, * presence of diabetes mellitus * presence of neurological problems * presence of osteoarthritis
effect of supragingival control versus supra- and subgingival control in the periodontal health during the maintenance

Conditions: Periodontitis

Summary: seventy patients will be previously treated for moderate-to-severe periodontitis according to their individual needs. thirty days after completion of periodontal treatment, these patients will be randomized to one of the following groups of periodic preventive maintenance (ppm): g1 - performed only control supragingival; g2 - performed supra and subgingival control (when necessary). the maintenance consultations will be scheduled every 3 months for 24 months. the hypothesis is that the effect of the supragingival control (conducted over 24 months) will be similar to the effect of the supra- and subgingival control combined, above the restoration and progression of periodontitis.

this randomized clinical trial, single-blind, aims to compare the effect of the supragingival biofilm control with the effect of supra- and subgingival biofilm control, performed by the patient-professional binomial, in periodontal patients treated, above the restoration and progression of periodontitis during the preventive periodic maintenance (ppm). seventy patients with moderate-to-severe periodontitis, aged from 35 years, will be included. participants will be periodontally treated according to their needs. after 30 days of the end of treatment, participants will be randomized (stratified for smoking) in two groups: group 1 (g1)- supragingival biofilm control; group 2 (g2)- supra and subgingival biofilm control. mpp consultation will take place every 3 months, for 24 months, in which the g1 will only receive procedures of supragingival biofilm control, and g2 will receive, beyond the supragingival control, subgingival interventions.

Eligibility criteria:
inclusion criteria: * age from 35 years; * present at least 12 teeth in the mouth; * patients diagnosed with moderate-to-severe periodontitis according to the criteria of the aap (1999): * to present ≥ 2 interproximal sites with al ≥ 6 mm and ≥1 interproximal site with pd ≥ 5 mm; or * to present ≥ 2 interproximal sites with al ≥ 3mm or ≥ 2 interproximal sites with pd ≥ 5 mm (in different teeth). exclusion criteria: * presence of systemic conditions unfavorable to periodontal treatment (diabetes, cardiovascular changes with antimicrobial prophylaxis indicated); * positive history of periodontal treatment and maintenance in the 12 months preceding the study; * positive history of using anti-inflammatory drugs and antibiotics in the 3 months prior to initial consultation; * patients in use of fixed orthodontic appliance; * pregnant patients.

Keywords: dental biofilm periodontitis maintenance randomized clinical trial biomarkers bacterias gingival crevicular fluid
cbm588 reduces colorectal polyp recurrence

Conditions: Colorectal Polyp

Summary: the goal of this randomized crossover clinical trial is to evaluate the efficacy of clostridium butyricum miyairi 588 (cbm588) in reducing colorectal adenomatous polyp recurrence in adult patients with a history of colorectal polyps. the main questions it aims to answer are: * does cbm588 reduce the recurrence of colorectal adenomatous polyps? * does cbm588 lead to a sustained decrease in polyp burden over time? researchers will compare a group receiving cbm588 in the first year to a group receiving cbm588 in the second year (after a washout period) to determine whether cbm588 effectively lowers polyp recurrence rates and adenoma prevalence.

this randomized crossover clinical trial evaluates the effect of clostridium butyricum miyairi 588 (cbm588), a butyrate-producing probiotic, on colorectal adenomatous polyp recurrence. participants who had undergone complete polypectomy were randomly assigned into two groups: * group a: received cbm588 for one year, followed by a washout period and no treatment in the second year. * group b: did not receive cbm588 in the first year but received it in the second year after a washout period. annual colonoscopy assessments were conducted to evaluate polyp count, type, and location. the primary outcome measure is adenoma recurrence. this study was conducted at a tertiary medical center and received institutional review board (irb) approval (kmuhirb-f(i)-20170010). all participants provided informed consent.

Eligibility criteria:
inclusion criteria: * adults with a history of colorectal adenomas that had been completely removed by endoscopic resection within the past three years, and who presented with recurrent colorectal polyps detected during surveillance colonoscopy * willingness to undergo follow-up colonoscopies at study intervals * no antibiotic or probiotic use for at least three months before study entry * written informed consent obtained exclusion criteria: * history of colorectal cancer or other gastrointestinal malignancies * diagnosis of inflammatory bowel disease or familial adenomatous polyposis * use of antibiotics and other probiotics during the study period

Keywords: gut microbiota butyrate-producing bacteria probiotic therapy colorectal neoplasia prevention
conventional vs ultrathin bronchoscopy for peripheral pulmonary lesions

Conditions: Lung Cancer

Summary: this study's purpose is to evaluate whether the use of an ultra-thin bronchoscope can improve sensitivity and diagnostic yield in peripheral pulmonary nodules. the ultra-thin probe is expected to reach further bronchi and allow to reach peripheral lesions. moreover, the ability to identify molecular pattern of lung cancer is essential nowadays, and it will be therefore evaluated.

142 patients with at least one peripheral pulmonary nodule will be enrolled. they will underwent randomization in 2 arms: patients in the first arm will undergo transbronchial needle aspiration with a conventional bronchoscope patients in the second arm will undergo transbronchial needle aspiration with a ultra-thin bronchoscope. every bronchoscopy will be performed by the same operator and will contemplate 3 passes for each nodule, followed by rapid on-site evaluation (rose) assessed by a dedicated cytologist. if the cytological on-site evaluation is negative in patients in the first arm, they will be shifted to the second arm. histological and molecular diagnosis will be assessed by a dedicated pathologist. data will be collected and analyzed.

Eligibility criteria:
inclusion criteria: * age ≥ 18years; * presence of at least one peripheral pulmonary lesion ≤ 3 cm on ct scan; * ability to give an informed consent. exclusion criteria: * coagulopathy or bleeding diathesis that cannot be corrected; * severe refractory hypoxemia; * unstable hemodynamic status; * inability to give an informed consent.

Keywords: peripheral pulmonary nodules ultrathin bronchoscope transbronchial needle aspiration
stellate ganglion block in longstanding facial nerve palsy patients

Conditions: Stellate Ganglion; Facial Palsy; Pain Management

Summary: the goal of the present study is to verify the efficacy of stellate ganglion block (sgb) in the treatment of facial pain


Eligibility criteria:
inclusion criteria: * facial nerve palsy patients exclusion criteria: 1. light of a recent myocardial infarction. 2. anticoagulant use 3. glucoma 4. lateral nerve palsy 5. emphysema 6. cardiac conduction abnormalities 7. active infection, flu, cold 8. uncontrolled cough 9. fever 10. very high blood pressure or if you are on blood thinners. 11. allergic reaction to local anesthetics 12. primary and secondary coagulopathy.

Keywords: stellate gangliom facial palsy
an extension study to assess impact of multiple sclerosis (ms) on physical function and provide continued ocrelizumab treatment

Conditions: Multiple Sclerosis

Summary: the study will evaluate the physical impact of ms from participant's perspective, provide continued access to ocrelizumab and assess the safety and tolerability of ocrelizumab.


Eligibility criteria:
inclusion criteria: * participants who were on ongoing ocrelizumab treatment on one of the following parent-studies \[studies mn39159/consonance (nct03523858), bn42082/musette (nct04544436), bn42083/gavotte (nct04548999), bn44083/globeam, mn43978/consonance ext., wa40404/o'hand (nct04035005), mn43964/olero (nct05269004), gn41791/fentrepid (nct04544449), bp46016/mintaka, cn41144/ocarina i-sc (nct03972306), cn42097/ocarina ii-sc (nct05232825)\] at the time of roll-over and who do not have access to the ocrelizumab treatment locally. * the first dose of study treatment in this extension study will be received no earlier than 5 months after the last treatment in the parent study. * negative urine pregnancy test within 24 hours to first dose administered on mn45053 study treatment in participants of childbearing potential. exclusion criteria: * study treatment is commercially marketed in the participant's country for the participant specific disease and is reasonably accessible to the participant. * study treatment is available via post trial access program (ptap) in the participant's country and is accessible to the participant. * permanent premature discontinuation of study treatment for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable). * any condition that, in the opinion of the investigator, would interfere with the interpretation of participant safety or place the participant at high risk for treatment-related complications. * concurrent participation in any therapeutic clinical trial (other than the parent study). * immunocompromised state * known active malignancy or are being actively monitored for recurrence of malignancy. * known presence of other neurological disorders.

Keywords: ocrelizumab
sublingual analgesia for acute abdominal pain in children

Conditions: Abdominal Pain

Summary: acute abdominal pain is a frequent symptom in children admitted to the emergency department . in the past the fear of masking a surgical condition has justified withholding analgesia in patients with acute abdominal pain. by the 2000s, some clinical trials established that opioid analgesia before surgical consultation does not affect diagnostic accuracy or outcome in children with acute abdominal pain. despite this, acute abdominal pain is still undertreated in this setting. published paediatric trials studied the effect of opioid analgesia administered by parenteral route or by mouth. to the best of our knowledge no study investigated the effectiveness of sublingual analgesia. the purpose of this randomized controlled trial is to assess the effectiveness of three different drugs (ketorolac, tramadol, paracetamol), administered by the sublingual route, in children complaining of acute abdominal pain.


Eligibility criteria:
inclusion criteria: * age 4 to 18 years * emergency department admission for moderate to severe acute abdominal pain (vas/nrs score \>=6) * informed consent signed by parents or legal guardians exclusion criteria: * known allergy or sensitivity to nonsteroidal anti-inflammatory drug, opioids or acetaminophen * use of analgesic drugs in the 8 hours before * clinical suspicion of abdominal pain due to fecal stasis * moderate or severe dehydration (weight loss of more than 5%) * known nephropathy, liver disease, metabolic or neurologic disease * thrombocytopenia or history of bleeding disease

Keywords: acute abdominal pain sublingual analgesia children ketorolac tramadol paracetamol analgesia